news
Gene therapy bolsters Parkinson’s drug benefits in pre-clinical study
The gene therapy restored the ability of neurons to convert levodopa to dopamine and may help develop therapies to slow disease progression.
List view / Grid view
Neuroprotection
news
Scientists identify protein that prevents HSV-1 brain damage
Mammalian target of rapamycin complex 2 (mTORC2) was found to prevent brain damage in mice infected with herpes simplex virus 1 (HSV-1).
news
Measuring microRNAs in blood may indicate dementia risk
Researchers identified three microRNAs whose levels were associated with mental performance in cells, mice and humans.
news
Mission Therapeutics receives $500k grant for Parkinson’s research
Mission Therapeutics was granted $500,000 from the The Michael J Fox Foundation for Parkinson’s Research for DUB inhibitor testing.
news
Stealth BioTherapeutics reports positive pre-clinical data for ALS candidate
Stealth BioTherapeutic's SBT-272 improved mitochondrial motility in a murine model of amyotrophic lateral sclerosis.
news
Chemotherapy drug reverses Alzheimer’s symptoms in mice
Axitinib, a common chemotherapy drug, restored memory and cognitive function in mouse models, representing a potential Alzheimer’s treatment.
news
NINDS awards Sinopia $3.3m for development of Parkinson’s drug candidate
Sinopia has been awarded a $3.3 million Fast-Track SBIR grant to fund the study for its small molecule candidate for Parkinson’s disease.
news
Promising pre-clinical data announced for Parkinson’s drug
Stealth BioTherapeutics reported positive data from a pre-clinical study evaluating SBT-272 in a murine model of Parkinson's disease.
news
Ground-breaking small molecule attenuates neuroinflammation in mice
Limiting neuroinflammation was shown to be a promising approach to treat neurological diseases such as stroke and spinal cord injury in mice.
article
An integrated vaccination approach to neurodegeneration
Guided by precise biomarker tests, therapeutic vaccines targeting the pathology of neurodegenerative disease could provide solutions to the impending global crisis in dementia. As Dr Andrea Pfeifer, Co-Founder, Chief Executive Officer and Director of AC Immune, describes here, current work is both establishing the targets that those vaccines must address…
news
Nasal drugs show promise for slowing Parkinson’s disease
Two different peptides were found to slow the spread of alpha-synuclein, potentially becoming the first drugs to slow the progression of Parkinson’s disease.
news
Researchers identify specific drug targets for a variety of brain disorders
Scientists have discovered drug targets in the neural circuits that encode memories, paving the way for the treatment of brain disorders.
news
IAIPs shown to reduce ischemic stroke damage in pre-clinical study
Inter-alpha inhibitor proteins (IAIP) demonstrated efficiency in reducing damage from an ischemic stroke, reveals pre-clinical study.
news
TREM2 regulation to prevent neurodegeneration is possible, study shows
Scientists used a synthetic thyroid hormone in mice to regulate the TREM2 gene implicated in diseases such as Alzheimer’s and Parkinson’s.
news
Prize winner uncovers how microbiome can combat neurodegeneration
Eran Blacher has won the NOSTER & Science Microbiome Prize for discovering the link between the microbiome and neurodegenerative diseases.
